Affibody Signs LOI with SHINE to Secure Lu-177 for ABY-271 Trials

Affibody AB has signed a Letter of Intent with SHINE Technologies, LLC to secure high‑quality non‑carrier‑added lutetium‑177 for its clinical radioligand therapy programs, naming the lead candidate ABY‑271 as an initial recipient of supply. The agreement positions SHINE as an additional supplier of n.c.a. Lu‑177 to support Affibody’s development work.

Affibody announced the LOI on February 19, 2026, identifying Stockholm, Sweden as the company’s base and describing SHINE as a U.S.‑based isotope producer. Affibody said the supply arrangement will support ABY‑271, a Lu‑177‑conjugated, HER2‑targeted Affibody® molecule currently in a first‑in‑human Phase 1 study in HER2‑positive metastatic breast cancer, and other Radioligand Therapy programs derived from the company’s proprietary platform.

David Bejker, CEO of Affibody, framed the LOI as a supply‑chain milestone for the company’s RLT pipeline. “The Letter of Intent with SHINE represents an important step in strengthening the supply chain for our Radioligand Therapy projects,” Bejker said. “Reliable access to high quality Lu 177 is essential as we advance ABY 271 through clinical development and continue to expand our Radioligand Therapy pipeline.”

SHINE’s role in the deal is underpinned by its prior clinical supply activity. In March 2022 SHINE Technologies, LLC provided highly pure n.c.a. Lu‑177 to ImaginAb to support preclinical and clinical radiopharmaceutical therapy programs; ImaginAb’s CEO Ian Wilson said at the time that partnering with SHINE offered access to “what we feel will become one of the largest and most reliable sources in the world for this isotope.” SHINE’s Therapeutics division produces n.c.a. Lu‑177, described as a low‑energy beta‑particle emitter that can be paired with a targeting molecule to irradiate cancer cells, and SHINE has said its fusion technology is expected to scale without the reactor shutdown constraints that have recently disrupted supply.

Affibody’s disclosure makes clear the current arrangement is a Letter of Intent and does not specify commercial terms. The company’s materials state the parties “may explore an option to extend this arrangement to include commercial Lu‑177 supply for ABY‑271, should the program successfully progress to commercialization,” but they do not list volumes, delivery schedules, pricing or whether the LOI is binding.

Affibody positions ABY‑271 as its lead RLT candidate within a pipeline the company describes as focused on oncology indications with high unmet need. Affibody’s corporate contact block lists its mailing address as Scheeles väg 2, SE‑171 65 Solna, Sweden and an email of reception@affibody.com; the phone line in the posted contact block appears duplicated as “+46 (0)8 59 88 38 008 59 88 38 00)” and is likely a typographic error in the posted materials.

If the ABY‑271 program advances through clinical development toward commercialization, both companies have signaled an intent to negotiate expanded supply terms; for now, the LOI secures SHINE as an additional clinical‑supply source of n.c.a. Lu‑177 as Affibody continues its Phase 1 human study in HER2‑positive metastatic breast cancer.